Osmond Matthew J, Dabertrand Fabrice, Quillinan Nidia, Su Enming J, Lawrence Daniel A, Marr David W M, Neeves Keith B
Department of Bioengineering University of Colorado Denver, Anschutz Medical Campus Denver Colorado USA.
Department of Anesthesiology University of Colorado Anschutz Medical Campus Denver Colorado USA.
Bioeng Transl Med. 2025 Mar 3;10(4):e70012. doi: 10.1002/btm2.70012. eCollection 2025 Jul.
Rapid restoration of blood flow is critical in treating acute ischemic stroke. Current thrombolytic therapies using tissue plasminogen activator (tPA) are limited by low recanalization rates and risks of off-target bleeding. Here, we demonstrate that a remarkably simple adjustment-using micrometer-scale rather than sub-micrometer particles to immobilize tPA-fundamentally improves thrombolysis. By merely increasing the particle diameter from 0.1 to 1.0 μm, we achieve a dramatic shift in lysis dynamics: 1.0 μm tPA-beads generate higher plasmin flux, readily overcome antiplasmin inhibition, and trigger a self-propagating cascade of fibrinolysis. This leads to near-complete clot dissolution at tPA doses nearly 100-fold lower than standard free tPA, both in vitro and in a murine model of acute ischemic stroke. Within minutes, low-dose 1.0 μm tPA beads fully restore blood flow, outperforming conventional therapies. Our results show that simply scaling up particle size can resolve kinetic and transport barriers in thrombolysis, offering a promising advancement in stroke treatment with potential applications in other thrombotic disorders.
快速恢复血流在急性缺血性中风治疗中至关重要。目前使用组织纤溶酶原激活剂(tPA)的溶栓疗法受限于低再通率和非靶向出血风险。在此,我们证明了一个非常简单的调整——使用微米级而非亚微米级颗粒固定tPA——从根本上改善了溶栓效果。仅仅将颗粒直径从0.1微米增加到1.0微米,我们就在溶解动力学上实现了显著转变:1.0微米的tPA珠产生更高的纤溶酶通量,易于克服抗纤溶酶抑制,并引发自我传播的纤维蛋白溶解级联反应。这导致在体外和急性缺血性中风小鼠模型中,tPA剂量比标准游离tPA低近100倍时,凝块几乎完全溶解。在几分钟内,低剂量的1.0微米tPA珠就能完全恢复血流,优于传统疗法。我们的结果表明,简单地扩大颗粒尺寸可以解决溶栓中的动力学和运输障碍,为中风治疗带来有前景的进展,并可能应用于其他血栓性疾病。